Arrhythmias & electrophysiology
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials
Authors' conclusion
Overall, midodrine was the only agent shown to reduce spontaneous syncopal events.
Study context
- Population
- Patients with vasovagal syncope
- Participants
- 1,744 patients28 studies
- Comparison
- Pharmacologic therapies vs each other and placebo
- Outcome
- Spontaneous VVS recurrence
Methodological detailsrandom-effect network meta-analysis, pairwise meta-analysis vs placebo, SUCRA ranking, Search of PubMed, Embase, Web of Science and Cochrane Library
- Random-effect network meta-analysis
- Pairwise meta-analysis vs placebo
- SUCRA ranking
- Search of PubMed, Embase, Web of Science and Cochrane Library
Pooled result
As reported in the abstract
Each group vs placeboRelative risk (95% CI)
Midodrine
0.55(0.35–0.85)
Fluoxetineespecially in patients with concomitant anxiety
0.36(0.16–0.84)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Positive head-up tilt test (lower level of evidence)Midodrinevs Placebo | 0.37 (0.23–0.59) | |
| Positive head-up tilt test (lower level of evidence)Atomoxetinevs Placebo | 0.49 (0.28–0.86) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials. Heart Rhythm. Published 9 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →